Vanguard Personalized Indexing Management’s Aclaris Therapeutics ACRS Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.8K	Buy	+17,558	New	+$59.2K	﹤0.01%	2016

Other funds holding ACRS

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Adage Capital Partners

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vanguard Personalized Indexing Management's ACRS Position: Q1 2026 in Review

Vanguard Personalized Indexing Management opened a new position in Aclaris Therapeutics (ACRS) in Q1 2026: 17,558 shares worth $65.8K. The stake represents ﹤0.01% of the portfolio and ranks #2016 among its holdings.

136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

Vanguard Personalized Indexing Management held 17,558 shares of Aclaris Therapeutics worth $65.8K as of Q1 2026.
Aclaris Therapeutics was a new Vanguard Personalized Indexing Management position in Q1 2026.
Aclaris Therapeutics made up ﹤0.01% of Vanguard Personalized Indexing Management's portfolio in Q1 2026, its #2016 holding.
136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Vanguard Personalized Indexing Management's 13F filing for Q1 2026, filed 14 May 2026.